$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn

$vrdn Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000159075020000053 Filed on May 08, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$828.0K	$372.0K
YoY Change	122.58%	-92.22%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.720M	$3.360M
YoY Change	-19.05%	12.37%
% of Gross Profit
Research & Development	$6.103M	$8.751M
YoY Change	-30.26%	36.46%
% of Gross Profit
Depreciation & Amortization	$68.00K	$73.00K
YoY Change	-6.85%	5.8%
% of Gross Profit
Operating Expenses	$8.826M	$12.11M
YoY Change	-27.11%	28.77%
Operating Profit	-$7.998M	-$11.74M
YoY Change	-31.85%	154.08%
Interest Expense	-$50.00K	$110.0K
YoY Change	-145.45%	-375.0%
% of Operating Profit
Other Income/Expense, Net	$95.00K	$339.0K
YoY Change	-71.98%	102.99%
Pretax Income	-$8.040M	-$11.63M
YoY Change	-30.87%	149.57%
Income Tax
% Of Pretax Income
Net Earnings	-$8.044M	-$11.63M
YoY Change	-30.83%	149.5%
Net Earnings / Revenue	-971.5%	-3126.08%
Basic Earnings Per Share
Diluted Earnings Per Share	-$2.653M	-$5.646M
COMMON SHARES
Basic Shares Outstanding	53.07M shares	30.92M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$36.10M	$51.00M
YoY Change	-29.22%	-34.7%
Cash & Equivalents	$36.10M	$18.20M
Short-Term Investments	$0.00	$32.80M
Other Short-Term Assets	$2.200M	$3.200M
YoY Change	-31.25%	-5.88%
Inventory
Prepaid Expenses
Receivables	$4.000K	$6.000K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$38.34M	$54.21M
YoY Change	-29.27%	-37.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$443.0K	$691.0K
YoY Change	-35.89%	17.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$50.00K
YoY Change		0.0%
Total Long-Term Assets	$709.0K	$741.0K
YoY Change	-4.32%	15.96%
TOTAL ASSETS
Total Short-Term Assets	$38.34M	$54.21M
Total Long-Term Assets	$709.0K	$741.0K
Total Assets	$39.05M	$54.95M
YoY Change	-28.94%	-36.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.629M	$517.0K
YoY Change	215.09%	-31.97%
Accrued Expenses	$3.055M	$3.044M
YoY Change	0.36%	-9.86%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.000M	$3.300M
YoY Change	21.21%
Total Short-Term Liabilities	$8.661M	$6.860M
YoY Change	26.25%	65.82%
LONG-TERM LIABILITIES
Long-Term Debt	$3.400M	$7.100M
YoY Change	-52.11%	-29.0%
Other Long-Term Liabilities		$41.00K
YoY Change		-68.7%
Total Long-Term Liabilities	$3.400M	$41.00K
YoY Change	8192.68%	-68.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.661M	$6.860M
Total Long-Term Liabilities	$3.400M	$41.00K
Total Liabilities	$12.05M	$13.99M
YoY Change	-13.89%	-2.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$176.2M	-$137.9M
YoY Change	27.75%	40.38%
Common Stock	$531.0K	$309.0K
YoY Change	71.84%	2.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$27.00M	$40.96M
YoY Change
Total Liabilities & Shareholders Equity	$39.05M	$54.95M
YoY Change	-28.94%	-36.83%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$8.044M	-$11.63M
YoY Change	-30.83%	149.5%
Depreciation, Depletion And Amortization	$68.00K	$73.00K
YoY Change	-6.85%	5.8%
Cash From Operating Activities	-$8.459M	-$11.81M
YoY Change	-28.37%	60.43%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$37.00K
YoY Change	-100.0%	-61.05%
Acquisitions
YoY Change
Other Investing Activities	$2.000M	-$2.780M
YoY Change	-171.94%
Cash From Investing Activities	$2.001M	-$2.820M
YoY Change	-170.96%	2868.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$19.75M	$138.0K
YoY Change	14214.49%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$17.72M	$218.0K
YoY Change	8026.15%	-99.43%
NET CHANGE
Cash From Operating Activities	-$8.459M	-$11.81M
Cash From Investing Activities	$2.001M	-$2.820M
Cash From Financing Activities	$17.72M	$218.0K
Net Change In Cash	$11.26M	-$14.41M
YoY Change	-178.11%	-147.01%
FREE CASH FLOW
Cash From Operating Activities	-$8.459M	-$11.81M
Capital Expenditures	$0.00	$37.00K
Free Cash Flow	-$8.459M	-$11.85M
YoY Change	-28.59%	58.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	mgen	Class Of Warrant Or Right Expired In Period ClassOfWarrantOrRightExpiredInPeriod	10707	shares
CY2020Q1	mgen	Classof Warrantor Right Exercise Priceof Warrantsor Rights Exercised During Period ClassofWarrantorRightExercisePriceofWarrantsorRightsExercisedDuringPeriod	1.10
CY2020Q1	mgen	Classof Warrantor Right Expired In Period Weighted Average Grant Date Fair Value ClassofWarrantorRightExpiredInPeriodWeightedAverageGrantDateFairValue	52500
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001590750
CY2020Q1	mgen	Classof Warrantor Right Grantsin Period ClassofWarrantorRightGrantsinPeriod	7500000	shares
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	53077348	shares
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	mgen	Common Stock Voteper Share CommonStockVoteperShare	1	vote
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2019Q4	mgen	Contract With Customer Asset Incurred But Not Yet Billed ContractWithCustomerAssetIncurredButNotYetBilled	300000	USD
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	mgen	Contract With Customer Asset Incurred But Not Yet Billed ContractWithCustomerAssetIncurredButNotYetBilled	1000	USD
CY2020Q1	mgen	Employment Agreement Term Of Employee Health Coverage EmploymentAgreementTermOfEmployeeHealthCoverage	P3M
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	MIRAGEN THERAPEUTICS, INC.
CY2020Q1	mgen	Employment Agreement Total Compensation Due To Termination For Good Reason Or Resignation In Base Salary Term EmploymentAgreementTotalCompensationDueToTerminationForGoodReasonOrResignationInBaseSalaryTerm	P3M
CY2020Q1	mgen	Lessee Operating Lease Number Of Renewal Terms LesseeOperatingLeaseNumberOfRenewalTerms	2	renewal_term
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2019Q4	mgen	Accrued Legal Fees Current AccruedLegalFeesCurrent	284000	USD
CY2020Q1	mgen	Accrued Legal Fees Current AccruedLegalFeesCurrent	323000	USD
CY2019Q4	mgen	Accrued Liabilities Equipmentand Lab Materials AccruedLiabilitiesEquipmentandLabMaterials	1000	USD
CY2020Q1	mgen	Accrued Liabilities Equipmentand Lab Materials AccruedLiabilitiesEquipmentandLabMaterials	11000	USD
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2019Q4	mgen	Accrued Liabilityof Warrantson Temporary Equity AccruedLiabilityofWarrantsonTemporaryEquity	100000	USD
CY2020Q1	mgen	Accrued Liabilityof Warrantson Temporary Equity AccruedLiabilityofWarrantsonTemporaryEquity	100000	USD
CY2019Q4	mgen	Accrued Outsourcing Clinicaland Preclinical Studies AccruedOutsourcingClinicalandPreclinicalStudies	2259000	USD
CY2020Q1	mgen	Accrued Outsourcing Clinicaland Preclinical Studies AccruedOutsourcingClinicalandPreclinicalStudies	1012000	USD
CY2019Q1	mgen	Amortization Of Stock Issuance Costs AmortizationOfStockIssuanceCosts	1000	USD
CY2020Q1	mgen	Amortization Of Stock Issuance Costs AmortizationOfStockIssuanceCosts	30000	USD
CY2020Q1	mgen	Capital Stock Shares Authorized CapitalStockSharesAuthorized	105000000	shares
CY2019Q4	mgen	Long Term Debt Accumulated Accretion Of Final Payment Fee LongTermDebtAccumulatedAccretionOfFinalPaymentFee	669000	USD
CY2020Q1	mgen	Long Term Debt Accumulated Accretion Of Final Payment Fee LongTermDebtAccumulatedAccretionOfFinalPaymentFee	726000	USD
CY2020Q1	mgen	Non Cash Lease Expense NonCashLeaseExpense	75000	USD
CY2020Q1	mgen	Operating Lease Remaining Lease Term OperatingLeaseRemainingLeaseTerm	P0Y9M
CY2019Q1	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	100000	USD
CY2020Q1	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	100000	USD
CY2016	mgen	Sharebased Compensation Arrangement By Sharebased Payment Award Number Of Shares Authorized Percent Of Common Stock Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAuthorizedPercentOfCommonStockOutstanding	0.04
CY2020Q1	mgen	Sharebased Compensation Arrangementby Sharebased Payment Award Equity Awards Outstanding SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding	3732288	shares
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1096000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1629000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	108000	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4000	USD
CY2019Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	182000	USD
CY2020Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1000	USD
CY2019Q1	us-gaap	Accretion Expense AccretionExpense	94000	USD
CY2020Q1	us-gaap	Accretion Expense AccretionExpense	63000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5108000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3055000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	254000	USD
CY2020Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	282000	USD
CY2019Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	66000	USD
CY2020Q1	us-gaap	Accrued Rent Current AccruedRentCurrent	0	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3348000	USD
CY2020Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3374000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	183574000	USD
CY2020Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	202685000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1018000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	664000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1018000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	664000	USD
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4493000	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12341000	shares
CY2019Q4	us-gaap	Assets Assets	30262000	USD
CY2020Q1	us-gaap	Assets Assets	39050000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	29739000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	38341000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	2000000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	2000000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	36100000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32606000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18195000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24846000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36103000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14411000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	11257000	USD
CY2019Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	17.93
CY2020Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.13
CY2019Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	46522	shares
CY2020Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	7535815	shares
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	46522	shares
CY2020Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	7535815	shares
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1895040	shares
CY2020Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	6667000	USD
CY2019Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	32000	USD
CY2020Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	524000	USD
CY2020Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	4600000	USD
CY2020Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y1M28D
CY2019Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2020Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-11000	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3357000	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34861876	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53077348	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34861876	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53077348	shares
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	349000	USD
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	531000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11624000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8044000	USD
CY2020Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	-3000	USD
CY2019Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	7667000	USD
CY2020Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	27000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	73000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	68000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	508000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2723000	USD
CY2019Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2020Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2019Q1	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2020Q1	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-54000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	410000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-18000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-104000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-849000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2245000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	298000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-436000	USD
CY2019Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense	232000	USD
CY2020Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense	141000	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	136000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30262000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	39050000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10180000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	8661000	USD
CY2019Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	4328000	USD
CY2020Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	3389000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	218000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17715000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2820000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2001000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-11629000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-8044000	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11629000	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8044000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	339000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	95000	USD
CY2019Q4	us-gaap	Notes Payable NotesPayable	8304000	USD
CY2020Q1	us-gaap	Notes Payable NotesPayable	7366000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11809000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8459000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	61000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.06
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	700000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	300000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P3Y
CY2019Q4	us-gaap	Liabilities Liabilities	14508000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	12050000	USD
CY2019Q4	us-gaap	Notes Payable Current NotesPayableCurrent	3976000	USD
CY2020Q1	us-gaap	Notes Payable Current NotesPayableCurrent	3977000	USD
CY2020Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	12108000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	8826000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11736000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7998000	USD
CY2019Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	100000	USD
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	100000	USD
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	306000	USD
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	400000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	266000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	400000	USD
CY2020Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y12M
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	121000	USD
CY2020Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	81000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	5000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	0	USD
CY2020Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	1218000	USD
CY2019Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4000	USD
CY2020Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1068000	USD
CY2019Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	23783000	USD
CY2020Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	37000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2786000	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2234000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	138000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	19754000	USD
CY2019Q1	us-gaap	Proceeds From Repayment Of Loans By Employee Stock Ownership Plans ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans	84000	USD
CY2020Q1	us-gaap	Proceeds From Repayment Of Loans By Employee Stock Ownership Plans ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans	16000	USD
CY2019Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	21000000	USD
CY2020Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2000000	USD
CY2019Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2020Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	13000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3871000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3817000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	523000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	443000	USD
CY2019Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2020Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2019Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2020Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1000000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8751000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6103000	USD
CY2020Q1	us-gaap	Restructuring And Related Cost Cost Incurred To Date1 RestructuringAndRelatedCostCostIncurredToDate1	2200000	USD
CY2020Q1	us-gaap	Restructuring And Related Cost Expected Number Of Positions Eliminated RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated	44	position
CY2020Q1	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.50
CY2020Q1	us-gaap	Restructuring Charges RestructuringCharges	119000	USD
CY2020Q1	us-gaap	Restructuring Charges RestructuringCharges	100000	USD
CY2019Q4	us-gaap	Restructuring Reserve RestructuringReserve	1515000	USD
CY2020Q1	us-gaap	Restructuring Reserve RestructuringReserve	416000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-168169000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-176216000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-176200000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	372000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	828000	USD
CY2020Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	2557544	shares
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	664000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1018000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	3530773	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	1394475	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	4182404	shares
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	1999000	USD
CY2020Q1	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	84000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	16000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	134000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	13000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	51344000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	40956000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	15754000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	27000000	USD
CY2019Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	5000	USD
CY2020Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30886085	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	45476338	shares
CY2020Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with one financial institution.</font></div></div>
CY2020Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s </font><font style="font-family:inherit;font-size:10pt;">condensed consolidated</font><font style="font-family:inherit;font-size:10pt;"> financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Although these estimates are based on the Company’s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001590750-20-000053-index-headers.html	Edgar Link	pending
0001590750-20-000053-index.html	Edgar Link	pending
0001590750-20-000053.txt	Edgar Link	pending
0001590750-20-000053-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
mgen-20200331.xml	Edgar Link	completed
mgen-20200331.xsd	Edgar Link	pending
mgen-20200331_cal.xml	Edgar Link	unprocessable
mgen-20200331_def.xml	Edgar Link	unprocessable
mgen-20200331_lab.xml	Edgar Link	unprocessable
mgen-20200331_pre.xml	Edgar Link	unprocessable
mgen-q12020x10q.htm	Edgar Link	pending
mgen-q12020xex102.htm	Edgar Link	pending
mgen-q12020xex103yale.htm	Edgar Link	pending
mgen-q12020xex104svb.htm	Edgar Link	pending
mgen-q12020xex311.htm	Edgar Link	pending
mgen-q12020xex312.htm	Edgar Link	pending
mgen-q12020xex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
svbimage.jpg	Edgar Link	pending
svbimagea01.jpg	Edgar Link	pending
svbimagea02.jpg	Edgar Link	pending
svbimagea03.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn

2020 Q1 Form 10-Q Financial Statement

#000159075020000053 Filed on May 08, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRDN Viridian Therapeutics, Inc.\DE Stock $vrdn

2020 Q1 Form 10-Q Financial Statement

#000159075020000053 Filed on May 08, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn